Long-term real-world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 >=50% metastatic NSCLC.
Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Long-term real-world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 >=50% metastatic NSCLC. ### Output: Pembrolizumab